Zoledronic Acid

Active ingredient: Zoledronic Acid

In short: Zoledronic Acid Injection is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Zoledronic Acid Injection reduces the incidence of fractures (hip, vertebral, and non-vert

Forms & strengths5 mg in a 100 mL ready to infuse solution.
LabelSagent Pharmaceuticals
Label updatedOct 14, 2026

What is Zoledronic Acid used for?

Zoledronic Acid Injection is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Zoledronic Acid Injection reduces the incidence of fractures (hip, vertebral, and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, zoledronic acid injection reduces the incidence of new clinical fractures .

Zoledronic Acid Injection is indicated for prevention of osteoporosis in postmenopausal women .

Zoledronic Acid Injection is indicated for treatment to increase bone mass in men with osteoporosis .

Zoledronic Acid Injection is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months .

Zoledronic Acid Injection is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease . …

Zoledronic Acid dosage

Zoledronic Acid Injection must be administered as an intravenous infusion over no less than 15 minutes.

Patients must be appropriately hydrated prior to administration of Zoledronic Acid Injection .

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Intravenous infusion should be followed by a 10 mL normal saline flush of the intravenous line.

Administration of acetaminophen following Zoledronic Acid Injection administration may reduce the incidence of acute-phase reaction symptoms.

Caution: After removing the overwrap check for minute leaks by squeezing the inner bag firmly. If leaks are found, discard container as sterility may be compromised. Use only if solution is clear and the container is undamaged.

Preparation for Administration:

Close flow control clamp of administration set.

Remove cover from port at bottom of container.

Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. NOTE: See full directions on administration set carton.

Suspend container from hanger.

Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Zoledronic Acid Injection.

Open flow control clamp to expel air from set. Close clamp.

Regulate rate of administration with flow control clamp.

The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.

The recommended regimen is a 5 mg infusion given once every 2 years intravenously over no less than 15 minutes.

The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.

The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.

The recommended dose is a 5 mg infusion. The infusion time must not be less than 15 minutes given over a constant infusion rate.

Re-treatment of Paget's Disease

After a single treatment with Zoledronic Acid Injection in Paget's disease an extended remission period is observed. Specific re-treatment data are not available. However, re-treatment with Zoledronic Acid Injection may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, or in those patients who failed to achieve normalization of their serum alkaline phosphatase, or in those patients with symptoms, as dictated by medical practice.

Prior to administration of each dose of Zoledronic Acid Injection, obtain a serum creatinine and creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each Zoledronic Acid Injection dose. …

How to take Zoledronic Acid — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Information for Patients

Patients should be made aware that Zoledronic Acid Injection contains the same active ingredient (zoledronic acid) found in Zometa®, and that patients being treated with Zometa should not be treated with Zoledronic Acid Injection.

Zoledronic Acid Injection is contraindicated in patients with creatinine clearance less than 35 mL/min .

Before being given Zoledronic Acid Injection, patients should tell their doctor if they have kidney problems and what medications they are taking .

Zoledronic Acid Injection should not be given if the patient is pregnant or plans to become pregnant, or if she is breastfeeding .

There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates, including Zoledronic Acid Injection. Before being given Zoledronic Acid Injection, patients should tell their doctor if they are aspirin-sensitive.

If the patient had surgery to remove some or all of the parathyroid glands in their neck, or had sections of their intestine removed, or are unable to take calcium supplements they should tell their doctor. …

Warnings & precautions

Do not take this medicine if: Zoledronic Acid Injection is contraindicated in patients with the following conditions:

Hypocalcemia .

Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure .

Known hypersensitivity to zoledronic acid or any components of Zoledronic Acid Injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported .

Zoledronic Acid Injection contains the same active ingredient found in Zometa, used for oncology indications, and a patient being treated with Zometa should not be treated with Zoledronic Acid Injection.

Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Zoledronic Acid Injection. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) is highly recommended for these patients .

Hypocalcemia following Zoledronic Acid Injection administration is a significant risk in Paget's disease. All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration (2.8), Adverse Reactions (6.1), Patient Counseling Information (17)].

All osteoporosis patients should be instructed on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration (2.8), Adverse Reactions (6.1), Patient Counseling Information (17)].

A single dose of Zoledronic Acid Injection should not exceed 5 mg and the duration of infusion should be no less than 15 minutes . …

Zoledronic Acid side effects

The following clinically significant adverse drug reactions are described elsewhere in the labeling:

Drugs with Same Active Ingredient

Hypocalcemia and Mineral Metabolism

Renal Impairment

Osteonecrosis of the Jaw

Atypical Fractures Including Femoral Fractures

Musculoskeletal Pain

Patients with Asthma

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Treatment of Osteoporosis in Postmenopausal Women

The safety of Zoledronic Acid Injection in the treatment of postmenopausal osteoporosis was assessed in Study 1, a large, randomized, double-blind, placebo-controlled, multinational study of 7736 postmenopausal women aged 65 to 89 years with osteoporosis, diagnosed by BMD or the presence of a prevalent vertebral fracture. The duration of the trial was three years with 3862 patients exposed to Zoledronic Acid Injection and 3852 patients exposed to placebo administered once annually as a single 5 mg dose in 100 mL solution infused over at least 15 minutes, for a total of three doses. All women received 1000 to 1500 mg of elemental calcium plus 400 to 1200 international units of vitamin D supplementation per day.

The incidence of all-cause mortality was similar between groups: 3.4% in the Zoledronic Acid Injection group and 2.9% in the placebo group. …

Drug interactions

No in vivo drug interaction studies have been performed for Zoledronic Acid Injection. In vitro and ex vivo studies showed low affinity of zoledronic acid for the cellular components of human blood. In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL. In vivo studies showed that zoledronic acid is not metabolized, and is excreted into the urine as the intact drug.

Caution is advised when bisphosphonates, including zoledronic acid, are administered with aminoglycosides, since these agents may have an additive effect to lower serum calcium level for prolonged periods. This effect has not been reported in zoledronic acid clinical trials.

Caution should also be exercised when Zoledronic Acid Injection is used in combination with loop diuretics due to an increased risk of hypocalcemia.

Caution is indicated when Zoledronic Acid Injection is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs).

Renal impairment has been observed following the administration of zoledronic acid in patients with preexisting renal compromise or other risk factors . …

About this medicine

Zoledronic Acid Injection contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its structural formula is:

Zoledronic acid monohydrate is a white crystalline powder. Its molecular formula is C5H10N2O7P2 • H2O and a molar mass of 290.1 g/mol. Zoledronic acid monohydrate is highly soluble in 0.1N sodium hydroxide solution, sparingly soluble in water and 0.1N hydrochloric acid, and practically insoluble in organic solvents. The pH of the Zoledronic Acid Injection solution for infusion is approximately 6.0 to 7.0.

Zoledronic Acid Injection is available as a sterile solution in bags for intravenous infusion. One bag with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis.

Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP.

How it works: Zoledronic Acid Injection is a bisphosphonate and acts primarily on bone. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 164500d7-51cf-438a-8bee-7a7dce76ad7a. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone